Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely prescribed for diabetes and obesity, but studies have found evidence that the medications may also influence behavior, such as supporting impulse control and reducing substance use and alcohol consumption by potentially interacting with the brain’s reward and stress systems. New research in Criminology adds to this growing evidence. When investigators analyzed data from a 2025 nationally representative US survey involv